Strong Prescription Growth for Arcutis Biotherapeutics' Zoryve Franchise Supports Buy Rating
Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's Is How to Trade
Arcutis Biotherapeutics Price Target Raised to $20 From $18 at Needham
H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19
TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $20
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $19 to $20
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
MommaCrazy : give it time... they may short it down to steal a ton of shares. They do this on ARQT and my dumb butt averaged up.